Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.83 EUR | -1.19% | -3.49% | +20.99% |
May. 23 | Prysmian among best; euro advances on dollar | AN |
May. 15 | Farmacosmo, group revenues drop into single digits in first quarter | AN |
Valuation
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 73.01 | 26.66 | 32.21 | - | - |
Enterprise Value (EV) 1 | 67.79 | 26.66 | 34.46 | 34.36 | 34.41 |
P/E ratio | - | - | -10.4 x | -33.2 x | - |
Yield | - | - | - | - | - |
Capitalization / Revenue | 1.11 x | 0.37 x | 0.43 x | 0.4 x | 0.36 x |
EV / Revenue | 1.03 x | 0.37 x | 0.46 x | 0.43 x | 0.39 x |
EV / EBITDA | 138 x | -93.5 x | 36.3 x | 16.8 x | 10.4 x |
EV / FCF | - | - | -40.5 x | 57.3 x | 20.9 x |
FCF Yield | - | - | -2.47% | 1.75% | 4.79% |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 37,442 | 38,858 | 38,811 | - | - |
Reference price 2 | 1.950 | 0.6860 | 0.8300 | 0.8300 | 0.8300 |
Announcement Date | 3/31/23 | 4/12/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | 58.02 | 65.66 | 71.21 | 74.2 | 80.45 | 89.3 |
EBITDA 1 | - | 0.493 | -0.285 | 0.95 | 2.05 | 3.3 |
EBIT 1 | - | -1.56 | -3.192 | -1.8 | -0.8 | 0.4 |
Operating Margin | - | -2.38% | -4.48% | -2.43% | -0.99% | 0.45% |
Earnings before Tax (EBT) 1 | - | - | -4.179 | -2.2 | -0.9 | 0.5 |
Net income 1 | 0.4133 | -2.005 | -3.934 | -2.2 | -0.9 | 0.5 |
Net margin | 0.71% | -3.05% | -5.52% | -2.96% | -1.12% | 0.56% |
EPS 2 | - | - | - | -0.0800 | -0.0250 | - |
Free Cash Flow 1 | - | - | - | -0.85 | 0.6 | 1.65 |
FCF margin | - | - | - | -1.15% | 0.75% | 1.85% |
FCF Conversion (EBITDA) | - | - | - | - | 29.27% | 50% |
FCF Conversion (Net income) | - | - | - | - | - | 330% |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 4/14/22 | 3/31/23 | 4/12/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 2.25 | 2.15 | 2.2 |
Net Cash position 1 | - | 5.22 | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | 2.368 x | 1.049 x | 0.6667 x |
Free Cash Flow 1 | - | - | - | -0.85 | 0.6 | 1.65 |
ROE (net income / shareholders' equity) | - | - | - | -17.1% | -7.3% | 3.9% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex 1 | - | - | - | 1.45 | 1.45 | 1.45 |
Capex / Sales | - | - | - | 1.95% | 1.8% | 1.62% |
Announcement Date | 4/14/22 | 3/31/23 | 4/12/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+20.99% | 34.82M | |
+21.30% | 1,918B | |
+1.52% | 44.78B | |
+34.90% | 39.05B | |
+11.57% | 9.83B | |
-19.46% | 7.63B | |
+18.17% | 7.12B | |
-8.51% | 6.88B | |
-2.33% | 5.81B | |
+8.02% | 5.28B |
- Stock Market
- Equities
- COSMO Stock
- Financials Farmacosmo S.p.A.